Analysts come out bullish on Bind Therapeutics

|By:, SA News Editor

Analysts are weighing in on recently public Bind Therapeutics (BIND -1%), whose most advanced drug candidate is BIND-014, a PSMA targeting Accurin containing docetaxel.

Credit Suisse starts the shares at Outperform. Price target is $21.

Cowen initiates at Outperform with a $30 price target.

Stifel starts BIND at Buy. Price target is $20.

JMP initiates at Market Outperform. Price target is $30.